Supplementary Figure 1. Participant flow by treatment steps and strategies for 12-week outcomes. Antidepressants initiated, switched or combined were bupropion, desvenlafaxine, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, venlafaxine, and vortioxetine. Augmented drugs were buspirone, lithium, triiodothyronine, and atypical antipsychotics including aripiprazole, risperidone, olanzapine, quetiapine, and ziprasidone. Treatment strategies were continuing initial monotherapy (M), switching antidepressants (S), augmenting with other drugs (A), combination of other antidepressants (C), S+A, S+C, A+C, and S+A+C.